Avant Diagnostics (OTC: AVDX)  is a diagnostic company that focuses on the commercialization of a series of proprietary microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe diseases. The company’s premier product is OvaDx, a non-invasive proteomics diagnostic screening test for early detection of ovarian cancer. The company believes this test could be approved as the first pre-symptomatic screening test for ovarian cancer in the U.S., detecting all types and stages of ovarian cancer with high sensitivity and specificity. For more information, visit the company’s website at www.avantdiagnostics.com